Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Anti Nausea Drug Deemed Safe For Fetuses: Ben-Gurion U.
Metoclopramide, a drug approved in the U.S. for nausea, vomiting and heartburn poses no significant risks for the fetus according to a large cohort study published in the June 11 issue of the prestigious New England Journal of Medicine, "The Safety of Metoclopramide Use in the First Trimester of Pregnancy" (N Engl J Med 2009;360:24 June 11, 2009).
generic viagra online
Vermont Legislature Passes Law Regulating All Drug/Device Company Marketing, Requiring Disclosure Of Gifts To Doctors
The Vermont Legislature has passed legislation (S 48) that bans nearly all gifts from pharmaceutical and medical device companies to health care providers, administrators and facilities in the state, the New York Times reports. The legislation specifically would prohibit drug and device makers from giving providers no-cost meals. Vermont"s legislation would go further than similar laws in other states like Massachusetts and Minnesota by requiring drug and medical device manufacturers who give gifts to health providers to publicly disclose recipients" names and dollar amounts of payments and gifts. The measure would not require manufacturers to disclose payments for clinical research of products undergoing FDA review, the Times reports. The legislation also would eliminate a loophole that allows manufacturers to conceal certain expenses by claiming them as trade secrets. In a recent report, the Vermont Office of the Attorney General said that medical product makers spent about $2.9 million on promotional efforts to the state"s health care providers in fiscal year 2008 and that nearly half of the state"s 4,573 licensed providers had received some type of incentive from drugmakers in the same year. The report, which was developed prior to passage of the new legislation, offers only aggregate data, as 83% of the manufacturer-declared payments were deemed to be trade secrets, the Times reports.Gov. Jim Douglas (R) is expected to sign the law, which would take effect July 1. Several state medical groups -- including the Vermont Association for Mental Health and the Vermont Medical Society -- have indicated support for the legislation.Marjorie Powell, a senior lawyer for the Pharmaceutical Research and Manufacturers of America, said the requirements under the new law appear redundant with new voluntary guidelines the group has issued on physician gifting practices. She said, "We think this is unnecessary, and it is not going to improve patient care," adding, "It makes it onerous not only for the company but also for the physician in Vermont, because this is going to be on a Web site" (Singer, New York Times, 5/20).
News of the day
Increase Global Productivity By Giving Eyeglasses To All In Need
Huge economic gains could be made if eyeglasses were provided to approximately 150 million people in need, according to research published today in the international public health journal, the Bulletin of the World Health Organization.
Oncology

ASH And EHA Jointly Announce Translational Research Training In Hematology Program

In an effort to foster global biomedical research that will ultimately lead to new and improved treatments for patients with blood diseases, the American Society of Hematology (ASH) and the European Hematology Association (EHA) have collaborated to create the Translational Research Training in Hematology (TRTH) program. This program will provide promising translational investigators an opportunity to undertake intensive training in the causes, diagnosis, and experimental treatment of hematologic disorders from some of the most recognized names in the field. "The next generation of translational researchers will need to understand how to direct research in both the European and U.S. systems," said TRTH co-director and past ASH president Kenneth Kaushansky, MD. "This unique cross-cultural program provides participants with ongoing mentoring, a supportive peer network, and a depth of knowledge and experience that will help position them as global leaders in the field of translational research." The inaugural TRTH will bring 20 early-career scientists to Marbella, Spain, during the week of March 20-26, 2010. Practical sessions will focus on career development, featuring career retrospectives from leaders in the field of hematology and panel discussions on grant preparation and funding s; while instructional sessions will prepare participants to conduct hypothesis-driven research, design phase I and II clinical trials, and utilize animal models, diagnostics, and biomarkers in translational research. "This rigorous one-week training course will allow participants to work with faculty in small groups to review and refine their individual research proposals," said program co-director and EHA president Willem Fibbe, MD. "The goal is for each of them to leave here with a competitive proposal so that they are ready to take the next step in applying for funding. We look forward to hearing about their progress when the group reconvenes at the ASH and EHA annual meetings." Medical trainees, biomedical trainees, and pharmaceutical doctorate trainees generally within 12 years of MD graduation or with less than eight years of post-doctoral experience are encouraged to apply; trainees must be an EHA or ASH member. Applications will be available on the ASH and EHA Web sites starting June 15, 2009. The American Society of Hematology is the world"s largest professional society concerned with the causes and treatment of blood disorders. Its mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems, by promoting research, clinical care, education, training, and advocacy in hematology. In September, ASH launched Blood: The Vital Connection , a credible online re addressing bleeding and clotting disorders, anemia, and cancer. It provides hematologist-approved information about these common blood conditions including risk factors, preventive measures, and treatment options. The European Hematology Association aims to promote excellence in clinical practice, research, and education in European hematology. Today, EHA - with over 3,000 active members from 95 countries - is a consolidated organization that pursues a large and growing number of projects and programs. European Hematology Association


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009